Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer

Ovarian Cancer Clinical Trial

Official title:

Phase II Trial of Fulvestrant in Treatment of Recurrent Ovarian Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00617188
• Other study ID #: CDR0000582821
• Secondary ID: UMN-2007LS003UMN
• Status: Completed
• Phase: Phase 2
• First received: February 14, 2008
• Last updated: December 3, 2017
• Start date: June 2007
• Est. completion date: July 2008

Study information

• Verified date: December 2017
• Source: Masonic Cancer Center, University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Estrogen can cause the growth of ovarian epithelial cancer cells. Hormone therapy using fulvestrant may fight ovarian cancer by blocking the use of estrogen by the tumor cells.

PURPOSE: This phase II trial is studying how well fulvestrant works in treating patients with recurrent ovarian epithelial cancer.

Description:

OBJECTIVES:

Primary

• To determine the 90-day clinical benefit (defined as the sum of complete responses, partial responses, and stable disease) in patients with recurrent ovarian epithelial cancer treated with single agent fulvestrant.

Secondary

• To establish the time to termination of treatment (due to all causes including progression and intolerance) for patients treated with this drug.

• To describe the toxicities observed in patients treated with this drug.

• To evaluate the quality of life of patients treated with this drug.

• To determine the effect that prolonged estrogen receptor antagonism has on markers of bone mineral turnover.

OUTLINE: Patients receive fulvestrant intramuscularly on days 1 and 15 of course 1 and then on day 1 of all subsequent courses. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients in continued response at the end of 1 year may continue treatment at the discretion of the treating physician.

Urinary N-telopeptide and serum skeletal-specific alkaline phosphatase are assessed at baseline and at 1, 3, and 6 months during study to determine the influence of estrogen blockade on bone mineral turnover.

Quality of life is assessed at baseline and every 3 months during treatment, and at the end of treatment using The Functional Assessment of Cancer Therapy - Ovarian (FACT-O) cancer questionnaire.

After completion of study treatment, patients are followed at approximately 30 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: July 2008
• Est. primary completion date: April 2008
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed ovarian epithelial carcinoma

• Recurrent or persistent disease

• Must have received greater than or equal to (=) 2 prior cytotoxic chemotherapy regimens, including = 1 platinum-containing regimen

• Disease not amenable to curative treatment with surgery and/or radiotherapy

• Must have measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) and/or a serum cancer antigen 125 (CA-125) level that is rising and meets 1 of the following criteria:

• Serum CA-125 level greater than (>) upper limit of normal (typically 35 µ/mL) on two evaluations at least 2 weeks apart

• Serum CA-125 level less than (<) 35 µ/mL but has risen progressively > 200% over successive specimens = 2 weeks apart

• Estrogen receptor-positive tumor

• Gynecologic Oncology Group (GOG) performance status 0-3

• Platelet count = 50 x 10^9/Liter

• Serum creatinine less than or equal to (=) 2.5 mg/deciliter

• Bilirubin = 1.5 times upper limit of normal (ULN)

• Serum glutamic oxaloacetic transaminase (SGOT) = 3 times upper limit of normal (ULN)

• alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 2.5 times ULN (= 5 times ULN in the presence of liver metastases)

• Alkaline phosphatase = 3 times ULN

• Prothrombin time-International Normalized Ratio (INR) = 1.6

• Not pregnant or nursing

• Negative pregnancy test

• Must be sterile or fertile patients must use effective contraception (i.e., double method including = 1 barrier, injectable, implantable, condoms plus spermicide)

• Prior malignancy allowed provided the patient has been disease-free for = 5 years

• Patients with previously diagnosed basal cell skin cancer are eligible immediately after completing therapy

• No history of bleeding (i.e., disseminated intravascular coagulation or clotting factor deficiency)

• No documented sensitivity to active or inactive excipients of fulvestrant (i.e., castor oil or mannitol)

• Recovered from the effects of prior surgery, radiotherapy, and/or chemoradiotherapy

• At least 3 weeks since prior chemotherapy

• At least 3 weeks since prior complete radiotherapy regimen alone or chemoradiotherapy

• An incomplete radiotherapy regimen (< 500 Gray) is allowed within the 3-week time frame

Exclusion Criteria:

• Concurrent hormone replacement therapy

• Prior long-term anticoagulation therapy other than anti-platelet therapy

Related Conditions & MeSH terms

• Ovarian Cancer

Intervention

Drug:
• Fulvestrant
Fulvestrant, 500 milligrams (mg) intramuscularly (IM) on Day 1, 250 mg IM on Day 15, and 250 mg IM on Day 29 and every 28 days thereafter until either intolerance or disease progression.

Locations

Country	Name	City	State
United States	Masonic Cancer Center at University of Minnesota	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

References & Publications (1)

Argenta PA, Thomas SG, Judson PL, Downs LS Jr, Geller MA, Carson LF, Jonson AL, Ghebre R. A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol Oncol. 2009 May;113(2):205-9. doi: 10.1016/j.ygyno.2009.01. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patients' Overall 90-Day Clinical Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST)	Best response recorded from the start of treatment until Day 90. Defined by the sum of the Complete Responses (CR), Partial Responses (PR) and Stable Disease (SD) in patients treated with fulvestrant. CR=disappearance of all lesions, PR=>or =30% decrease in sum of all target lesions, Progressive Disease (PD) =>or=20% increase in sum of all target or any new lesions, SD=not CR, PR or PD.	Day 90
Secondary	Patients' Overall 90-Day Clinical Response as Measured by Modified Response Evaluation Criteria in Solid Tumors (Rustin)	Defined by the sum of Complete Responses (CR), Partial Responses (PR) and Stable Disease (SD) in patients treated with fulvestrant. CR=normalization of serum CA-125 level from 2 initially elevated samples, PR=>or=50% decrease in serum CA-125 level from 2 initially elevated samples, Progressive Disease (PD)=CA-125 two times the upper limit of normal on 2 occasions (if previously normalized) OR CA-125 two times nadir (lowest value) on 2 occasions if elevated at initiation of treatment, SD=not CR, PR or PD.	Day 90
Secondary	Median Number of Days to Treatment Termination	Time is determined from first dose to termination due to all causes.	Up to 373 Days
Secondary	Mean Scores - Quality of Life Assessment	Functional Assessment of Cancer Therapy-Ovarian Cancer (FACT-O)Version 1/23/07 - This is a relative quality of life assessment; 100 = Best, 0 = Worst. It was developed and validated with cancer patients and includes physical well being, social well being, emotional well being and relationship with doctor subscales and can be summed into one total quality of life score. It is a standardized scale which collects data (scores 1-4) from 47 questions. Answers are transformed into a number between 0-100. Mean was calculated by adding up the values of the scores and dividing by the number of scores.	Baseline, 3 Months Post Treatment, 6 Months Post Treatment
Secondary	Serum Skeletal-Specific Alkaline Phosphatase Concentration	Median Bone mineral results - assessed by serum skeletal-specific alkaline phosphatase laboratory results collected from patients in study.	Baseline, 1 Month, 3 Months, 6 Months
Secondary	Urine N-telopeptide Concentration	Median bone mineral results - assessed by serial urine N-telopeptide laboratory results collected from patients.	Baseline, 1 Month, 3 Months, 6 Months